Lung carcinoma is subdivided into small cell carcinoma and non-small cell carcinoma (NSCLC). NSCLC is heterogeneous group of carcinomas and accounts for 70-80% of lung cancer. NSCLC is further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been cha...

As discussed in the “Non–Small-Cell Lung Cancer” chapter, there are two major subdivisions of lung cancer: small-cell lung cancer (SCLC) and non–small-cell lung cancer (NSCLC). SCLC is decreasing in frequency in the United States, with recent data showing it represents only 14% of lung cancers. This chapter provides information on the staging and prognosis, pathology and pathophysiology, treatm...

Lung cancer is the major form of cancer resulting in cancer-related mortality around the world. MicroRNAs are endogenous small non-coding single-stranded RNAs, which can engage in the regulation of gene expression. In this study, miR-18a-5p significantly upregulated in non-small cell lung cancer (NSCLC) tissues and NSCLC cell lines, suggesting an oncogenic function in lung cancer. Additionally,...

In recent years, lung cancer has been the most commonly diagnosed cancer globally; 1.6 million people died of lung cancer in 2012 globally, making lung cancer the leading cause of cancer-related deaths. Lung cancer can be mainly histologically classified into two types: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), accounting for approximately 85% and 15% of cases, respe...

For a very long time, lung cancer was major health problem and the leading cause of death worldwide. Small cell (SCLC) accounts for 15% cases non-small (NSCLC) 85% cases. Although many people believe that smoking is primary cancer, there are numerous other contributing factors as well. Nonsmokers have higher risk from radon than smokers do. Smoke household fuel, infections caused by bacteria vi...

Lung cancer is the leading cause of cancer death. Non-small cell lung cancer (NSCLC), including the squamous cell carcinoma, large cell carcinoma and adenocarcinoma subtypes, accounts for more than 80% of primary lung cancer cases. Understanding the mechanisms underlying NSCLC metastasis is essential for the improvement of anticancer therapies. Recent studies have shown that microRNAs (miRNAs) ...

We thank Dr Degens et al. for their interesting comments. Our study aimed at evaluating the relationship between survival of patients receiving immune checkpoint inhibitors (ICPI, targeting PD-1 - PD-L1 pathway) and sarcopenia or cachexia in non-small cell lung cancer (NSCLC). took into account other known predictive factors ICPI efficiency, particularly tissue immunostaining score all patients...

Targeted therapy (TT) has revolutionized cancer treatment, successfully applied in various settings. Adjuvant TT resected early-stage gastrointestinal stromal tumors (GIST), melanoma, non-small cell lung (NSCLC), and breast led to practice-changing achievements. In particular, standard treatments include BRAF inhibitors for osimertinib NSCLC, hormone or HER2 cancer, imatinib GIST. Despite the u...

The small nuclear ribonucleoprotein polypeptides B And B′ (SNRPB) is a core component of spliceosome and plays key role in pre-mRNA splicing. Emerging evidence suggests that it involves the development several types cancer. Our previous study has demonstrated SNRPB highly expressed non-small-cell lung cancer (NSCLC) functions as an oncogene. However, whether contributes to cisplatin resistance ...

The tumor microenvironment (TME) plays critical roles in immune modulation and malignancies the process of cancer development. Immune cells constitute a significant component TME influence migration metastasis cells. Recently, number therapeutic approaches targeting have proven promising already been used to treat different types cancer. In particular, PD-1 PD-L1 inhibitors first-line setting n...